# ChosenMed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chosenmed

- Industry: Healthcare
- Headquarters: Beijing, China
- Website: www.chosenmedtech.com
- Total disclosed funding: $16M
- Latest round: Series C (Dec 20, 2021)
- Investors on record: 8

## About

Based in Beijing, China and established in 2017, ChosenMed operates as an oncology precision medicine product and service provider that provides tumor genetic testing service. The company has many strategic partners, such as Illumina, Qiagen and Agena. ChosenMed has set up several standardized oncology NGS medical testing laboratories in Beijing, Hangzhou, Nanjing, Chongqing and Guangzhou. Dr. Wei Li, the Chief Scientist, is a tenured professor at the University of California, and the Chief Information Officer, Dr. Beifang Niu, is a researcher at the Chinese Academy of Sciences.

ChosenMed provides oncology precision medicine product and service for early tumor screening, companion diagnosis, dynamic monitoring and prognostic evaluation fields. The product of the company includes solid tumor and blood tumor, such as chosenOne599® pan-cancer gene detection, chosenLung™ lung cancer 27 gene test and chosenHeme® blood tumor-related gene detection program. The company has mass spectrometry platform, micro-droplet digital polymerase chain reaction (PCR) platform and tumor high-throughput sequencing platform, such as novaseq 6000, miseq dx and nextseq 2000. The company has 57 patents and 62 life letter software copyrights. The company adopts genetic testing and artificial intelligence technology.

## Funding rounds

- Series C, Dec 20, 2021 — Yijing Investment, Hangzhou Linzhuo Industry Fund
- Series C, Oct 8, 2021 — Hunan Hi-Tech Venture Capital, Yijing Investment, Jingming Capital
- Series B, Apr 20, 2020 — Delta Capital, HighLight Capital, MED-FINE Capital, Shanghai Lianhe Investment
- Series A, May 2, 2018, $16M — Delta Capital, HighLight Capital, MED-FINE Capital

## Investors

- Delta Capital (https://capitalatlas.ai/funds/delta-capital) — Series A, Series B
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series A, Series B
- MED-FINE Capital (https://capitalatlas.ai/funds/med-fine-capital) — Series A, Series B
- Shanghai Lianhe Investment — Series B
- Hunan Hi-Tech Venture Capital (https://capitalatlas.ai/funds/hunan-hi-tech-venture-capital) — Series C
- Yijing Investment (https://capitalatlas.ai/funds/yijing-investment) — Series C
- Jingming Capital (https://capitalatlas.ai/funds/jingming-capital) — Series C
- Hangzhou Linzhuo Industry Fund — Series C